Nippon Chemiphar, Torii Pharmaceutical to Terminate Sales Tie-up for Urinary Alkalizer.Tokyo, Japan, Mar 13, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Nippon Chemiphar and Torii torii Symbolic gateway marking the entrance to Shinto shrines or other sacred spots in Japan. It has many variations, but it characteristically consists of two cylindrical posts topped by a crosswise rectangular beam extending beyond the posts on either side and a second Pharmaceutical have agreed to terminate their existing partnership for Uralyt-U and Uralyt Tablets, two urinary alkalizers that they are jointly marketing in Japan, on the expiration date, September 30. Accordingly, Nippon Chemiphar will be a sole distributor of the agents in Japan from October 1. Uralyt-U and Uralyt-Tablets, which were developed by German pharmaceutical company Madaus, is indicated for the treatment of acid urine in patients with gout and hyperuricemia hyperuricemia /hy·per·uri·ce·mia/ (-u?ri-se´me-ah) uricemia; an excess of uric acid in the blood.hyperurice´mic hy·per·u·ri·ce·mi·a n. An unusually high concentration of uric acid in the blood. as well as acidosis acidosis /ac·i·do·sis/ (as?i-do´sis) 1. the accumulation of acid and hydrogen ions or depletion of the alkaline reserve (bicarbonate content) in the blood and body tissues, decreasing the pH. 2. . Nippon Chemiphar and Torii Pharmaceutical entered into the sales partnership in June 1992. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion